GlassScriptPhysician profile
Abyaz Asmar
NPI 1891476412
$2,170.38
in general payments reported to CMS, 2019-2025
20 companies · $744 in 2025
The $744 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $197 · 2024: $1,229 · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,170.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $354.53 | 2024-2025 | |
| Abbvie INC. | $226.45 | 2023-2025 | Botox |
| Ucb, INC. | $220.06 | 2024-2025 | Rystiggo, Briviact |
| Genentech USA, INC. | $207.74 | 2024-2025 | Evrysdi, Ocrevus Zunovo, Ocrevus |
| Acadia Pharmaceuticals INC | $199.56 | 2024-2025 | Nuplazid, Daybue |
| Argenx US, INC. | $171.73 | 2024-2025 | Vyvgart Hytrulo |
| Csl Behring | $170.76 | 2023-2025 | Hizentra |
| Sk Life Science, INC. | $165.46 | 2024 | Xcopri |
| Eisai INC. | $86.94 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.31 | 2024-2025 | Hyqvia |
| Astrazeneca Pharmaceuticals LP | $62.80 | 2024 | Wainua |
| Springworks Therapeutics, INC. | $43.52 | 2025 | Gomekli |
| Genzyme Corporation | $41.70 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $26.15 | 2024 | Ultomiris |
| Neurelis, INC. | $23.27 | 2023 | Valtoco |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $22.12 | 2025 | Spinraza |
| Janssen Pharmaceuticals, INC | $21.79 | 2024 | Xarelto |
| Grifols USA, LLC | $19.57 | 2025 | Gamunex-C |
| Janssen Biotech, INC. | $17.32 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $13.60 | 2023 | Nuedexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abyaz Asmar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.